Publications

Chung A, Banbury B, Vignali M, Huang CY, Asoori S, Johnson R, Kurtz T, Arora S, Wong SW, Shah N, Martin TG, Wolf JL. Antibody and T-cell responses by ultra-deep T-cell receptor immunosequencing after COVID-19 vaccination in patients with plasma cell dyscrasias. British journal of haematology. 2022. PMID: 36041779

Hoimes CJ, Flaig TW, Milowsky MI, Friedlander TW, Bilen MA, Gupta S, Srinivas S, Merchan JR, McKay RR, Petrylak DP, Sasse C, Moreno BH, Yu Y, Carret AS, Rosenberg JE. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022. PMID: 36041086

Rugo HS, Tolaney SM, Loirat D, Punie K, Bardia A, Hurvitz SA, O'Shaughnessy J, Cort?s J, Di?ras V, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo M, Itri LM, Kalinsky K. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer. 2022. PMID: 36038616

Haas ND, Viele C, Paul SM, Abrams G, Smoot B, Melisko M, Levine JD, Miaskowski C, Kober KM. Polymorphisms in Cytokine Receptor and Regulator Genes are Associated with Levels of Exercise in Women Prior to Breast Cancer Surgery. Biological research for nursing. 2022. PMID: 36036249

Schwab ME, Shao S, Zhang L, Lianoglou B, Belter L, Jarecki J, Schroth M, Sumner CJ, MacKenzie T. Investigating attitudes toward prenatal diagnosis and fetal therapy for spinal muscular atrophy. Prenatal diagnosis. 2022. PMID: 36029101

Rugo HS, Bardia A, Marm? F, Cortes J, Schmid P, Loirat D, Tr?dan O, Ciruelos E, Dalenc F, Pardo PG, Jhaveri KL, Delaney R, Fu O, Lin L, Verret W, Tolaney SM. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022. PMID: 36027558

Shy BR, Vykunta VS, Ha A, Talbot A, Roth TL, Nguyen DN, Pfeifer WG, Chen YY, Blaeschke F, Shifrut E, Vedova S, Mamedov MR, Chung JJ, Li H, Yu R, Wu D, Wolf J, Martin TG, Castro CE, Ye L, Esensten JH, Eyquem J, Marson A. High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails. Nature biotechnology. 2022. PMID: 36008610

Song H, Bucher S, Rosenberg K, Tsui M, Burhan D, Hoffman D, Cho SJ, Rangaswami A, Breese M, Leung S, Ventura MVP, Sweet-Cordero EA, Huang FW, Nijagal A, Wang B. Single-cell analysis of hepatoblastoma identifies tumor signatures that predict chemotherapy susceptibility using patient-specific tumor spheroids. Nature communications. 2022. PMID: 36008377

Carnevale J, Shifrut E, Kale N, Nyberg WA, Blaeschke F, Chen YY, Li Z, Bapat SP, Diolaiti ME, O'Leary P, Vedova S, Belk J, Daniel B, Roth TL, Bachl S, Anido AA, Prinzing B, Ibañez-Vega J, Lange S, Haydar D, Luetke-Eversloh M, Born-Bony M, Hegde B, Kogan S, Feuchtinger T, Okada H, Satpathy AT, Shannon K, Gottschalk S, Eyquem J, Krenciute G, Ashworth A, Marson A. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature. 2022. PMID: 36002574

Hilton J, Cristea M, Postel-Vinay S, Baldini C, Voskoboynik M, Edenfield W, Shapiro GI, Cheng ML, Vuky J, Corr B, Das S, Apfel A, Xu K, Kozicki M, ?nsal-Ka?maz K, Hammell A, Wang G, Ravindran P, Kollia G, Esposito O, Coker S, Diamond JR. BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial. Cancers. 2022. PMID: 36077617

Alderuccio JP, Ai WZ, Radford J, Solh M, Ardeshna KM, Lunning MA, Hess BT, Zinzani PL, Stathis A, Carlo-Stella C, Hamadani M, Kahl BS, Ungar D, Kilavuz T, Yu E, Qin Y, Caimi PF. Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study. Blood advances. 2022. PMID: 35790100

Dame Idossa, Hala T. Borno, Katarina Wang, Mark Pletcher, Gillian Gresham, Alison J. Canchola, Douglas S. Bell, Michael Matheny, Lisa Schilling, Amy M. Perkins, Kai Zheng, Lucila Ohno-Machado, Jihoon Kim, Spencer L. Soohoo, Daniella Meeker, Scarlett Gomez. Ethnic and Racial Inequities in Cancer Screening During the COVID-19 Pandemic: a multi-site observational study in the United States. International Journal of Cancer Care and Delivery. 2022. PMID:

Zheng YJ, Ho W, Sanlorenzo M, Vujic I, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S. Melanoma risk during immunomodulating treatment. Melanoma research. 2022. PMID: 35993892

Talukder R, Makrakis D, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, Carril-Ajuria L, Castellano D, de Kouchkovsky I, Jindal T, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Tripathi N, Agarwal N, Vather-Wu N, Zakharia Y, Morales-Barrera R, Devitt ME, Cortellini A, Fulgenzi CAM, Pinato DJ, Nelson A, Hoimes CJ, Gupta K, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Lu E, Kumar V, Lorenzo GD, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Wright JL, Yu EY, Montgomery RB, Hsieh AC, Grivas P, Khaki AR. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma. Clinical genitourinary cancer. 2022. PMID: 36155169

Chen HY, Bok RA, Cooperberg MR, Nguyen HG, Shinohara K, Westphalen AC, Wang ZJ, Ohliger MA, Gebrezgiabhier D, Carvajal L, Gordon JW, Larson PEZ, Aggarwal R, Kurhanewicz J, Vigneron DB. Improving multiparametric MR-transrectal ultrasound guided fusion prostate biopsies with hyperpolarized 13 C pyruvate metabolic imaging: A technical development study. Magnetic resonance in medicine. 2022. PMID: 35975978

Zhu Z, Turner NC, Loi S, Andr? F, Martin M, Di?ras V, Gelmon KA, Harbeck N, Zhang C, Cao JQ, Yan Z, Lu DR, Wei P, VanArsdale TL, Rejto PA, Huang X, Rugo HS, Loibl S, Cristofanilli M, Finn RS, Liu Y. Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib. NPJ precision oncology. 2022. PMID: 35974168

Moasser MM. Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions. Cancer research. 2022. PMID: 35731927

Zhu AX, Dayyani F, Yen CJ, Ren Z, Bai Y, Meng Z, Pan H, Dillon P, Mhatre SK, Gaillard VE, Hernandez S, Kelley RK, Sangro B. Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022. PMID: 35435967

Tamukong PK, Kuhlmann P, You S, Su S, Wang Y, Yoon S, Gong J, Figlin RA, Janes JL, Freedland SJ, Halabi S, Small EJ, Rini BI, Kim HL. Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma. Urologic oncology. 2022. PMID: 35973929

Rugo HS, Bianchini G, Cortes J, Henning JW, Untch M. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. ESMO open. 2022. PMID: 35964548